Galapagos Regains Rights to GLPG1690 For Pulmonary Fibrosis, Announces End of Partnership with Janssen
Belgian based biotech firm Galapagos, a company that specializes in the discovery and development of molecular medicines with new drug targets, announced that its seven year proprietary investment agreement with Janssen Pharmaceuticals, part of the Johnson & Johnson healthcare brand, has been terminated by mutual agreement between the two…
